Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

被引：1

作者：

Platzbecker, Uwe ^{[1
]}

Germing, Ulrich ^{[2
]}

Giagounidis, Aristoteles ^{[3
]}

Goetze, Katharina ^{[4
]}

Kiewe, Philipp ^{[5
]}

Mayer, Karin Tina ^{[6
]}

Ottmann, Oliver ^{[7
]}

Radsak, Markus ^{[8
]}

Wolff, Thomas ^{[9
]}

Haase, Detlef ^{[10
]}

Hankin, Monty ^{[11
]}

Wilson, Dawn ^{[11
]}

Zhang, Xiaosha ^{[11
]}

Laadem, Abderrahmane ^{[12
]}

Sherman, Matthew L. ^{[11
]}

Attie, Kenneth M. ^{[11
]}

机构：

[1] Carl Gustav Carus Techn Univ, Univ Klinikum, Dresden, Germany

[2] Univ Klinikum Dusseldorf, Dusseldorf, Germany

[3] Marien Hosp, Dusseldorf, Germany

[4] Tech Univ Munich, D-80290 Munich, Germany

[5] Onkol Schwerpunkt Oskar Helene Heim, Berlin, Germany

[6] Univ Hosp Bonn, Dept Internal Med 3, Bonn, Germany

[7] Goethe Univ Frankfurt, Univ Klinikum Frankfurt, D-60054 Frankfurt, Germany

[8] Johannes Gutenberg Univ Mainz, Univ Med Ctr, D-55122 Mainz, Germany

[9] OncoRes Lerchenfeld UG, Hamburg, Germany

[10] Univ Med Gottingen, Dept Hematol & Med Oncol, Gottingen, Germany

[11] Acceleron Pharma, Cambridge, MA USA

[12] Celgene Corp, Summit, NJ USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM THE PHASE 2 PACE-MDS STUDY
Platzbecker, U.
Germing, U.
Giagounidis, A.
Goetze, K.
Kiewe, P.
Mayer, K.
Ottmann, O.
Radsak, M.
Wolff, T.
Haase, D.
Hankin, M.
Wilson, D.
Zhang, X.
Laadem, A.
Sherman, M.
Attie, K.
[J]. HAEMATOLOGICA, 2015, 100 : 192 - 192
[2] Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study
Giagounidis, Aristoteles
Platzbecker, Uwe
Germing, Ulrich
Goetze, Katharina
Kiewe, Philipp
Mayer, Karin Tina
Ottmann, Oliver
Radsak, Markus
Wolff, Thomas
Haase, Detlef
Hankin, Monty
Wilson, Dawn
Zhang, Xiaosha
Laadem, Adberrahmane
Sherman, Matthew L.
Attie, Kenneth M.
[J]. BLOOD, 2015, 126 (23)
[3] Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study
Platzbecker, Uwe
Germing, Ulrich
Gotze, Katharina
Kiewe, Philipp
Wolff, Thomas
Mayer, Karin
Chromik, Joerg
Radsak, Markus
Donovan, Eileen
Wilson, Dawn M.
Zhang, Xiaosha
Laadem, Abderrahmane
Sherman, Matthew L.
Attie, Kenneth M.
Giagounidis, Aristoteles
[J]. BLOOD, 2016, 128 (22)
[4] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW-INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY
Platzbecker, U.
Giagounidis, A.
Germing, U.
Goetze, K.
Kiewe, P.
Mayer, K.
Chromik, J.
Radsak, M.
Wolff, T.
Donovan, E.
Wilson, D.
Zhang, X.
Laadem, A.
Sherman, M.
Attie, K.
[J]. HAEMATOLOGICA, 2016, 101 : 16 - 16
[5] Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study
Platzbecker, Uwe
Kiewe, Philipp
Germing, Ulrich
Gotze, Katharina S.
Mayer, Karin
Radsak, Markus P.
Wolff, Thomas
Chromik, Joerg
Wilson, Dawn
Zhang, Xiaosha
Rovaldi, Chris
Laadem, Abderrahmane
Sherman, Matthew Leigh
Attie, Kenneth Morris
Reynolds, Joseph
Linde, Peter Guest
Giagounidis, Aristoteles
[J]. BLOOD, 2017, 130
[6] Long-Term Efficacy and Safety of Luspatercept in Lower-Risk Myelodysplastic Syndromes (MDS): Phase 2 PACE-MDS Study
Platzbecker, Uwe
Kiewe, Philipp
Germing, Ulrich
Goetze, Katharina
Mayer, Karin
Radsak, Markus
Wolff, Thomas
Chromik, Joerg
Reynolds, Joseph
Barron, Carolyn
Zhang, Xiaosha
Laadem, Abderrahmane
Attie, Kenneth
Giagounidis, Aristoteles
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S319 - S320
[7] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
Platzbecker, U.
Germing, U.
Giagounidis, A.
Goetze, K.
Kiewe, P.
Mayer, K.
Ottmann, O.
Radsak, M.
Wolff, T.
Haase, D.
Hankin, M.
Wilson, D.
Zhang, X.
Laadem, A.
Sherman, M.
Attie, K.
[J]. LEUKEMIA RESEARCH, 2015, 39 : S25 - S25
[8] Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study.
Platzbecker, Uwe
Giagounidis, Aristoteles
Kiewe, Philipp M.
Germing, Ulrich
Gotze, Katharina S.
Mayer, Karin
Radsak, Markus
Wolff, Thomas
Chromik, Joerg
Reynolds, Joseph
Barron, Carolyn
Rovaldi, Chris
Suragani, Rajasekhar N. V. S.
Zhang, Xiaosha
Laadem, Abderrahmane
Linde, Peter G.
Sherman, Matthew L.
Oelschlaegel, Uta
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] A phase 2, ascending dose study of ACE-536 to treat anemia in low/intermediate-1 risk MDS patients: The PACE-MDS study
Platzbecker, U.
Attie, K.
Wilson, D.
Boyd, I.
Germing, U.
Goetze, K.
Giagounidis, A.
Kiewe, P.
Mayer, K.
Ottman, O.
Radsak, M.
Wolff, T.
Sherman, M.
[J]. LEUKEMIA RESEARCH, 2013, 37 : S167 - S167
[10] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY
Giagounidis, A.
Germing, U.
Goetze, K.
Kiewe, P.
Wolff, T.
Mayer, K.
Chromik, J.
Radsak, M.
Wilson, D.
Zhang, X.
Laadem, A.
Sherman, M. L.
Attie, K. M.
Linde, P. G.
Platzbecker, U.
[J]. HAEMATOLOGICA, 2017, 102 : 264 - 264

← 1 2 3 4 5 →